Opinion

Video

Selecting Between Receptor Pathway Inhibitors for mHSPC

Explore the complexities of treatment options for metastatic hormone-sensitive prostate cancer, emphasizing shared decision-making and patient considerations.

Therapeutic Decision-Making in Advanced Prostate Cancer

Key Themes:

  • Approach to selecting among multiple androgen receptor pathway inhibitors
  • Individualization of therapy based on patient factors
  • Consideration of drug-specific characteristics

Expert Insights:

  • Dr Shore provided guidance on approaching treatment decisions with multiple agents now available (enzalutamide, apalutamide, abiraterone, and darolutamide).
  • He emphasized the importance of individualizing therapy based on comorbidities, potential drug-drug interactions, convenience factors, and patient preferences.

The discussion noted darolutamide's lower central nervous system penetration and potentially improved tolerability in certain populations, while acknowledging that all these agents represent effective treatment options.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
1 expert is featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.